Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Endothelial Dysfunction in African Americans
NCT04769206Phase 2Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Dec 2021
- Primary completion
- May 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of galantamine in endothelial dysfunction, sponsored by Vanderbilt University Medical Center. Started Dec 2021; status: recruiting.
02
Drugs
galantamine
03
Conditions
endothelial dysfunction
Beyond the preview
Go deeper on NCT04769206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769206.